Researchers at Mount Sinai Investigate a Novel Class of Drugs for MPN Patients
Researchers in The Tisch Cancer Institute’s Myeloproliferative Neoplasms (MPN) Program at Mount Sinai is investing a novel class of drugs for MPN patients.
"Our hope is that idasanutlin will improve long-term survival in patients with chronic blood cancers,” says Dr. Hoffman, MD, at the Icahn School of Medicine at Mount Sinai. He says the mission is urgent because “there are no other agents currently available to improve the longevity of these individuals.”
Click HERE to read the full article from the Tisch Cancer Institute.